You all complain about drug commercials, and with good reason. They are equal parts cloying and annoying. Let's make fun of them, OK?
Wegovy and Ozempic, both GLP-1 agonists, have taken the world by storm, providing a simple way to lose weight without changing our lifestyle. A new report in Science helps us understand what we do not know: the known unknowns of obesity. Let me summarize.
A recent study linking marijuana use to schizophrenia attracted widespread attention. Now that the excitement has died down, let's take a closer look at the science. How does Pfizer's weight-loss pill compare to Ozempic, the obesity treatment beloved by celebrities the world over?
If you're one of the 100% of viewers who want to put a brick through your TV when one of the ceaseless, nauseating Ozempic ads comes on there's hope on the horizon. Pfizer has a pill that seems to work as well as the O-O-O-Ozempic injections. Perhaps this will shut up those wretched ads. A look at Pfizer's clinical trial data.
The two long-term drivers for weight loss and control are your basal metabolic rate, the number of calories you burn while your carcass is at rest, and your muscle tissue’s ability to perform and sustain physical activity for extended periods moving your carcass. Both are dependent on the amount of muscle tissue you have developed through conditioning or granted through genetics. So, before you decide to withdraw from your 401K to pay for your hit of Wegovy or Ozempic or any other miraculously pitched expensive weight loss drug, you need to consider some basic physiology.